{"ticker": {"uuid": "cea8868f-239c-4849-9c43-11d65bc0e0fe", "symbol": "NAUT", "name": "Nautilus Biotechnology Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology And 2 Promising Penny Stocks To Consider", "summary": "This article discusses three promising penny stocks for investors looking for growth opportunities in smaller companies: Nautilus Biotechnology (NAUT), Quantum-Si (QSI), and Butler National (BUKS). Nautilus and Quantum-Si are pre-revenue life sciences companies with strong cash p", "url": "https://www.sahmcapital.com/news/content/nautilus-biotechnology-and-2-promising-penny-stocks-to-consider-2026-07-10", "source_name": "Sahm", "published_at": "2026-07-11T14:10:29", "published_display": "11 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026", "summary": "Nautilus Biotechnology, Inc. (NASDAQ: NAUT) announced it will release its second-quarter 2026 financial results before market open on Tuesday, July 28, 2026. The company will host a webcasted conference call at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss these resu", "url": "https://finance.yahoo.com/healthcare/articles/nautilus-biotechnology-announce-second-quarter-120000347.html", "source_name": "Market source", "published_at": "2026-07-09T06:11:14", "published_display": "09 Jul 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology to announce Q2 2026 results on July 28", "summary": "Nautilus Biotechnology, Inc. (NASDAQ: NAUT) will release its second-quarter 2026 financial results on July 28, 2026, before the market opens. Following the announcement, the company will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a busin", "url": "https://scanx.trade/stock-market-news/companies/nautilus-biotechnology-to-announce-q2-2026-results-on-july-28/45063864", "source_name": "scanx.trade", "published_at": "2026-07-08T15:39:57", "published_display": "08 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology sets July 28 call on Q2 results", "summary": "Nautilus Biotechnology (NASDAQ:NAUT) will release its second-quarter 2026 financial results before market open on Tuesday, July 28, 2026. Management will host a webcast conference call at 5:30 a.m. PT / 8:30 a.m. ET to discuss results, business developments, and outlook. Historic", "url": "https://www.stocktitan.net/news/NAUT/nautilus-biotechnology-to-announce-second-quarter-2026-financial-f06w9g3vl4nr.html", "source_name": "Stock Titan", "published_at": "2026-07-08T12:11:55", "published_display": "08 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Nautilus Biotechnology, Inc. \u2013 NASDAQ:NAUT", "summary": "This page displays the \"Price to sales forward\" metric for Nautilus Biotechnology, Inc. (NASDAQ: NAUT). It is a finance-related data point available on TradingView, specifically under the company's financial overview. The content provided appears to be a stub or a section of a la", "url": "https://www.tradingview.com/symbols/NASDAQ-NAUT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T06:39:57", "published_display": "08 Jul 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Nautilus Biotechnology, Inc. \u2013 NASDAQ:NAUT", "summary": "This article provides access to the \"Enterprise value to EBIT forward\" for Nautilus Biotechnology, Inc. (NASDAQ: NAUT) via the TradingView platform. It appears to be a financial data page rather than an analytical article, indicating where users can find this specific financial m", "url": "https://www.tradingview.com/symbols/NASDAQ-NAUT/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T06:10:12", "published_display": "08 Jul 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A Nautilus Biotechnology For: 30 June By Investing.com", "summary": "This article reports on a Form 13D/A filing for Nautilus Biotechnology concerning the period up to June 30th. It originates from Investing.com and was published on June 30, 2026, at 22:20. The filing likely pertains to significant ownership stakes and changes in beneficial owners", "url": "https://ng.investing.com/news/stock-market-news/form-13da-nautilus-biotechnology-for-30-june-93CH-2581117", "source_name": "Investing.com Nigeria", "published_at": "2026-07-01T04:39:22", "published_display": "01 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Andreessen Horowitz trims Nautilus (NAUT) stake in June 2026 block trade", "summary": "Andreessen Horowitz-affiliated funds have filed an amended Schedule 13D for Nautilus Biotechnology, Inc. (NAUT), disclosing a reduction in their stake following a block trade on June 26, 2026, at $2.00 per share. Despite the sale, AH Bio Fund II and Andreessen Horowitz LSV Fund I", "url": "https://www.stocktitan.net/sec-filings/NAUT/schedule-13d-a-nautilus-biotechnology-inc-amended-major-shareholder-r-d88621180b28.html", "source_name": "Stock Titan", "published_at": "2026-07-01T03:10:22", "published_display": "01 Jul 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology, Inc.(NasdaqCM: NAUT) added to Russell 2000 Growth Benchmark", "summary": "Nautilus Biotechnology, Inc. (NasdaqCM: NAUT) has been added to the Russell 2000 Growth Benchmark. This inclusion is part of several recent additions to various Russell indices, reflecting increased recognition and market exposure for the biotechnology company. Nautilus Biotechno", "url": "https://www.marketscreener.com/news/nautilus-biotechnology-inc-nasdaqcm-naut-added-to-russell-2000-growth-benchmark-ce7f5fded188f326", "source_name": "marketscreener.com", "published_at": "2026-06-30T04:39:22", "published_display": "30 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology, Inc.(NasdaqCM:NAUT) added to Russell Small Cap Comp Growth Benchmark", "summary": "Nautilus Biotechnology, Inc. (NasdaqCM: NAUT) has been added to the Russell Small Cap Comp Growth Benchmark. This inclusion is part of a series of additions to various Russell indices, including the Russell 2500 Growth, Russell 2000, and Russell Microcap indices. The company, foc", "url": "https://www.marketscreener.com/news/nautilus-biotechnology-inc-nasdaqcm-naut-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdc8bf020", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T21:40:35", "published_display": "29 Jun 2026 21:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology, Inc.(NasdaqCM:NAUT) added to Russell Small Cap Comp Value Benchmark", "summary": "Nautilus Biotechnology, Inc. (NAUT) has been added to the Russell Small Cap Comp Value Benchmark, as announced on June 28, 2026. This inclusion is part of a series of additions to various Russell indexes, including Growth, 2500, 2000, 3000E, and Microcap benchmarks, reflecting th", "url": "https://www.marketscreener.com/news/nautilus-biotechnology-inc-nasdaqcm-naut-added-to-russell-small-cap-comp-value-benchmark-ce7f5fdfd08ff52d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T16:40:11", "published_display": "29 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology, Inc.(NasdaqCM: NAUT) added to Russell 2000 Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNaHg1RmkwTDBUX1VoVmxlcEU3V3dSODA3eExRU09WQlZBal9Xb2M5N0lXbjRuVDlfNzlWZEtkbVNUM2VubmNmZmdReDFfblUtWGhvOG1xS2R5VXVQMmcyMm5WVS1PYWQzMTRrdFR3R19fRk5aWTdaWUFiMmxadDI5WUJRbE43NU1va3lrLVBCTERQQVozeVFzLUtEdEdUZXc2bi1JWElYajB1Zmgzcy00XzFoYm05X2FybUZ4amVR?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology, Inc.(NasdaqCM: NAUT) added to Russell Microcap Index", "summary": "Nautilus Biotechnology, Inc. (NasdaqCM: NAUT) has been added to the Russell Microcap Index, a significant development for the life sciences company. This inclusion follows its additions to the Russell Microcap Value, Microcap Growth, Russell 2000 Growth, and Russell 3000E Growth ", "url": "https://www.marketscreener.com/news/nautilus-biotechnology-inc-nasdaqcm-naut-added-to-russell-microcap-index-ce7f5fdedd89ff26", "source_name": "marketscreener.com", "published_at": "2026-06-29T05:40:43", "published_display": "29 Jun 2026 05:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology, Inc.(NasdaqCM: NAUT) added to Russell 2500 Value Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQTFYxVl9ZU1dpaVpfY1VERU9wQmM2WDhXVUpkT05FWlJFRExrRFVhUHg3aGNLZkd1QS04bmt0RHF0djlpUkdWT2pnQTNiS3RRX0p2QzI4MmpSdUtHNmJ4cElqb24wZVowWElkdEduY1ZUeWd4RFAwclV0dFY4Q1FnbzAyRDBVUDJFNDdmTVhjTTNzaVZkdjNxdnpfSGNUUUlvWE9KOGxLT2RjRThRTlFoUGVaa2o4cTFIWFhuZUwySDAtTENHaV9MMXlLbw?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T22:00:00+00:00", "published_display": "28 Jun 2026 22:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology, Inc.(NasdaqCM: NAUT) added to Russell 2500 Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNSjBJTTB0SWJfcDIwRkRZOWMzakhyeDhtUlZzY3RKcUp6N3NnaDVEM2l5Q0dmMHk4bDBEeDZnUllWaVRDa3diRV9iMXFHMU9hM3RNbTh2NWQ5TUU1QWVxTHh5UlRZUEhDS0dmV090cVlPeGpwYlFna2w2ZVBNdGdGTk1lV0FjbVRLUHBrWUhIcjB2dlVvRnhxSVVaYjI1emptSDdkVk5scTkwYUlOM01IM0ExZHp4OGRucDBibEpR?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T22:00:00+00:00", "published_display": "28 Jun 2026 22:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology, Inc.(NasdaqCM: NAUT) added to Russell 3000E Value Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxObjNQdVJ5bDRMbVo4Z2UyNWRSVlBOUG83T3RTTGRLR2V5a3dWcUNwLUN6Q1NjUFJXNG14bVFDaGFuX1NydnhKX3E4ZW5RdGF1LUhfVUp4V1JCWTJOTEs2dWlLcFVzR012ZWt1d0lSOHJMVTZoMDdrOWR1aTMzV2hYUlo5NTlLRkdYNzE3bVF6MHg2YWlrZkhYNHgzLUZIOWtiZzRxRTc5eC0zc080VUE2dF80dEpBckJKRUs2Q1AxQ1ZIdHRaNERNa0ZFal8?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology Inc (NAUT) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Nautilus Biotechnology Inc (NAUT), focusing on support, resistance, indicators, and moving averages. It highlights that the relevant support and resistance data have not been disclosed, and the technical indicators and moving averages", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-naut/technical", "source_name": "TradingKey", "published_at": "2026-06-27T02:38:55", "published_display": "27 Jun 2026 02:38", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnolgy, Inc. Actuals & Estimates (NASDAQ:NAUT)", "summary": "This article provides financial actuals and estimates for Nautilus Biotechnology, Inc. (NASDAQ:NAUT), detailing its stock performance, analyst forecasts, and historical price movements. It includes information on current stock price, market capitalization, earnings reports, and a", "url": "https://www.tradingview.com/symbols/NASDAQ-NAUT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T13:38:55", "published_display": "26 Jun 2026 13:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Nautilus Biotechnology Reports First Quarter 2026 Financial Results", "summary": "This press release details Nautilus Biotechnology's financial results for the first quarter of 2026. It will likely cover key financial metrics such as revenue, expenses, and net income for the period, along with any significant operational highlights or future outlook.", "url": "https://www.moomoo.com/news/post/69023619/press-release-nautilus-biotechnology-reports-first-quarter-2026-financial-results", "source_name": "Moomoo", "published_at": "2026-06-26T04:09:41", "published_display": "26 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NAUT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for Nautilus Biotechnology, Inc. (NAUT) stock, noting that one analyst currently offers a 1-year price target of $4.00. It also includes key financial data, stock performance metrics, and responses to frequently asked questions abo", "url": "https://www.tradingview.com/symbols/NASDAQ-NAUT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T01:10:03", "published_display": "26 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology (NAUT) grants 45,000 stock options to director", "summary": "Nautilus Biotechnology, Inc. (NAUT) granted 45,000 stock options to director Karen Akinsanya on June 18, 2026, as part of her compensation. The options have an exercise price of $2.28 per share and expire on June 18, 2036. They will vest in equal monthly installments over 12 mont", "url": "https://www.stocktitan.net/sec-filings/NAUT/form-4-nautilus-biotechnology-inc-insider-trading-activity-23d2e0a7f060.html", "source_name": "Stock Titan", "published_at": "2026-06-23T00:11:48", "published_display": "23 Jun 2026 00:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Nautilus Biotechnology, Inc. Insider Trading Activity", "summary": "Nautilus Biotechnology director Matthew S. McIlwain received a grant of 45,000 stock options, with an exercise price of $2.28 per share and an expiration date of June 18, 2036. These options will vest over time, with one-twelfth vesting monthly, conditional on his continued servi", "url": "https://www.stocktitan.net/sec-filings/NAUT/form-4-nautilus-biotechnology-inc-insider-trading-activity-4acae952c5d8.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:34", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Nautilus (NAUT) granted 45,000 stock options vesting monthly", "summary": "Nautilus Biotechnology director Melissa B. Epperly was granted 45,000 stock options with an exercise price of $2.28 per share, expiring on June 18, 2036. These options vest in equal monthly installments over 12 months, contingent on her continuous service as a \"Service Provider\" ", "url": "https://www.stocktitan.net/sec-filings/NAUT/form-4-nautilus-biotechnology-inc-insider-trading-activity-d0a346376b25.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:34", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology (NAUT) investors approve directors, auditor and annual Say on Pay", "summary": "Nautilus Biotechnology, Inc. (NAUT) held its 2026 annual meeting where shareholders approved the election of Class II directors Parag Mallick and Farzad Nazem, ratified PricewaterhouseCoopers LLP as the independent auditor for 2026, and gave advisory approval to the 2025 executiv", "url": "https://www.stocktitan.net/sec-filings/NAUT/8-k-nautilus-biotechnology-inc-reports-material-event-7cf711df1db9.html", "source_name": "Stock Titan", "published_at": "2026-06-18T19:40:34", "published_display": "18 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Inc (PBYI) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMib0FVX3lxTFBLTlZKRkozaEk4eERFcjZIb0ZibktCNnJNSkVzdmhCd0ZFRzROcll0TjJiTVBqeG5iWlhlSlFybFdsdkV4Qkw5RFB5Wmd5MDBkbFZ2Z1NZX1ZfV1pxcGNjZFk1dEZjR21FRWNUQ2RqOA?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T05:53:20+00:00", "published_display": "18 Jun 2026 05:53", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology Inc (NAUT) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Nautilus Biotechnology Inc (NAUT), noting that relevant data for key metrics like P/E, P/B, P/S, and P/CF ratios have not yet been disclosed by the company. It briefly shows the current stock price, market cap, and indicates that the", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-naut/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T20:40:00", "published_display": "17 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology Inc (NAUT) Institutional Confidence", "summary": "This article provides details on the institutional confidence in Nautilus Biotechnology Inc (NAUT), including its stock price, market cap, and a breakdown of its TradingKey Stock Score dimensions. It lists significant institutional shareholders and their shareholdings, offering i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-naut/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T17:39:44", "published_display": "17 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology Inc (NAUT) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Nautilus Biotechnology Inc (NAUT), including analyst ratings and target prices. Two analysts rate NAUT as a \"Strong Buy,\" with a target price of $2.50, representing an 84.33% upside. The company's recent EPS was -$0.11 against an exp", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-naut/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T16:39:44", "published_display": "17 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: PDS Biotechnology beats Q1 2026 EPS expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOUTY4SzBROHBQYlRIT2Y0U2NWN1NHN0hlSkJHNXZMamhvN1dpRWVpNlZKb3I4UDAtOVZRS2dqNzRiTWZISUtTdlZVbldnZ3pfV1N0VXh0NWV0ckpMcUZGRDdaZGlXSEFZWktvdHVreUladmplcUJXLUpMYUxpMVBIOEJWSlJodnJhZjBHMlN6dF8zVUlRWHlHblFQZ3dNa1FWUDJ4eVVNMWVZZ0dVaWtsZEhBcTB2bFNROXE3VXFYQ3NJWXIxYjRYZw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTXNUdVZadGlGUFRyY004aWwyQUQ1eUhVLVRxbUJtWTVrSndNdFV0S0xJYjdPTlhUVmNxVDl3Q2Y4VnE0d280bDh3QlFOOUNHS2JtRExnX0FfWHozeUNKVDhpRjJLbHZjdHdEQ0hldlRZbTFKdVNqWFEzRlFCbkNOclYweTJCcnNvXzFXWWVRWEhnSXVPbVJwSUJSbldKQlFXUF8zOTdKYlRxUQ?oc=5", "source_name": "TradingView", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology (NASDAQ:NAUT) Is In A Good Position To Deliver On Growth Plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQMmRMYjRMeGktTkxNcVREX2NoejM1UEQ1X1RaN2VubG5TQjhBay1feHJ2OG9NYzd3cG9wQkNTMmVoSDZzaFZ2cHhudnBEN0psRE41eV9taFM1Uks4cGF2eW1TcnA1MmRPYnV3Nm9nQVdaa3UwZ0h5dHYzWEZHV2lSdGh3eDRMQ0lvY19sUFBZNW03eEJXWl9xZXVNZ0pLaGpmNE5qYkRWWQ?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology Inc (NAUT) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/nautilus-biotechnology-inc-naut-q1-070513982.html", "source_name": "GuruFocus.com", "published_at": "2026-04-29T07:05:13+00:00", "published_display": "29 Apr 2026 07:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/e2e50c21-45bb-3616-8296-0ced8fb69ee7/nautilus-biotechnology-q1.html", "source_name": "MarketBeat", "published_at": "2026-04-28T15:29:04+00:00", "published_display": "28 Apr 2026 15:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQUTY3Q1hBZmZrNXh6OGNucnFIc0NOMWd4NWJ3V09IMklYZHA5SUd3YmhWSEowUVlhNVhreDR2ZUVLczdBSm5MVDVmbDhhU0VEZlhwSHdpT05nN2dONzZlR3hjeFhfMk5yQU5TSkZacEZnY0pobGU0eWNoeEVHNDJKOHZQM3ptTE5oUXRyeE1HV1dmdzUxLW9GaElR?oc=5", "source_name": "Investing News Network", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is Why Nautilus Biotechnology (NAUT) is One of the Best Life Sciences Penny Stocks to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNOGlKa3VLUTFtQVNPVjRmeFlZZjdJUURSa1IxT0RnMlBYUUhFeklMNnI5TkpvYzZiVHp6bUJ6YUN5WXJHZk9QTjBpRm53bG5YLXh0MjlfcFYtQUpTQWMxRmVxT3o1UnNUbjBEUXBydjBteUdwWG1jd2g2UHpQa1lvM2F4VWphQ1BKakV1bUM0OFBXWk5Oa3E5aGdQNVpiUEhDYkZjUTg5WQ?oc=5", "source_name": "Market source", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology And 2 Other Compelling Penny Stocks For Your Watchlist", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQMlozM2lReGNNRlVEX2s0T3hfRTcwVEx4Ulo4TnVRZEpieWI4M1R0LUp6MjhlTkJpT3ctYTM4aW1TeklmM2tPZTRpdUx6NUNSVGFyYWNPZW1jWlNWMUNHZkpPR0JORThLREUwTFg1dmJyUmNNTTFRVmg4eHBnWm9sNzdtYWFSRmNpbnBJc25PakRiVDd2cm94eXNZYU9MRTdpSjVkZ3FtVlhiUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOTlBxUW9QV2o3YTF4RVdzWWlWUWZfU2V6Y25mcHBxM2RQTkpES0FqY0xsRDdtc0NqZE1KY2RFSWFfMGVCSVR2RXpndERPOFF6al9HQndCU2p0SkpPQ3dsc19BaVVvSzFxQ2FwcGEwVFlxNUFmZUUtdHpvVmpfQkFDX2FVLXprUQ?oc=5", "source_name": "Market source", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology Insiders May Regret Not Buying More, Market Cap Hits US$236m", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxQWDJaNzV0WDBiNHRkZ3ZKclBxSktReUhqMU80YjZXUFMxNmhvWDIzbHk0S3g5OUpfNXFuemNWQW1aLWgxSy1kWmZzeUQwRjlBRUxndTQwMTlGMmRZVm1Udmpld01UUGIyMFhzVVY4M1p0OUVKU24zajByLXBFZnJhOVJDNUxNZ1BzUjgxR2pTNHNWQlMxSF9fa3R6elF2SHpMd3V5V2YySV9EMktiX2s2QnVIZ3l6SUxmSk9zcTNpSlV1dUFyN2tGMFN1YnVncHFXQzUydVh2cVJhSUlHWllFZVNPcWY2RVhmUmQ5Q9IB8gFBVV95cUxNenpFUS0temt6TWlPdUs3cEUydFVSc3I2ZEhDM2k5TTliTEJrNHZUVTk1VDR5UDQ1OFVmeGF5c2Fhc1IwbXJ3ekF1YW1WemFoUWdjelh5bkZWcldqejNNSW5NX0VYV01MenpWX0tOWUYyS3hsNEhPUGxSRzlMUi1fYmFkMzVGX0pYcGZwZUVBZDU3MDJ5UGRYOWx0bnByVGFyWjRoSHQwTTRqSG9vand1Ylc5MTI5bktIQmpZaWxkUEtUU09rSWJ0ZWxzZ1RsMzhuMnVIQXNmRDhZN2xqUWg1dVdnNjNvX25hUTVMLXFnV19OQQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NAUT Stock Price and Chart \u2014 NASDAQ:NAUT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE4yTFRZV25WbVN4Mk1xQ2ZBQUZRNWozUTM2NUVhQXprREZDcjBfXzZYeW1TTjZ0cHBQdjgwVXZ6MTh6MUpMZWZzSXpQcDhwU256UDZOOENkZHJmMmRh?oc=5", "source_name": "TradingView", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top Nautilus Biotechnology (NAUT) Competitors 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVNKY3laekE3VnVNaGdPS05PUzV0MkxNb1dXNFRlNmhHWnpVcnlhZnlkUWZoV05DaEhvVE9yU2djeV9tR1I2NU5yNHlVTnFQWGNuWGhFcEpNcklyTkNHWGs1LTNTYjRfemhTSHhlQnkzVWVIR0o3WTYtMTJTOXR3VQ?oc=5", "source_name": "MarketBeat", "published_at": "2021-06-13T14:46:49+00:00", "published_display": "13 Jun 2021 14:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology (NAUT) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9nSlZVc2pVUjFHaVZRb3ZMNTg4N09INjF1R251OVN1Y1EwVHFuWWJmQzFTOFMwN2pBMXViQjBwMXI0akhtdHU0ODhWU0ZsVWNlSzN1NFNHT3pUUQ?oc=5", "source_name": "MarketBeat", "published_at": "2021-06-13T14:24:51+00:00", "published_display": "13 Jun 2021 14:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology And 2 Promising Penny Stocks To Consider", "summary": "This article discusses three promising penny stocks for investors looking for growth opportunities in smaller companies: Nautilus Biotechnology (NAUT), Quantum-Si (QSI), and Butler National (BUKS). Nautilus and Quantum-Si are pre-revenue life sciences companies with strong cash p", "url": "https://www.sahmcapital.com/news/content/nautilus-biotechnology-and-2-promising-penny-stocks-to-consider-2026-07-10", "source_name": "Sahm", "published_at": "2026-07-11T14:10:29", "published_display": "11 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026", "summary": "Nautilus Biotechnology, Inc. (NASDAQ: NAUT) announced it will release its second-quarter 2026 financial results before market open on Tuesday, July 28, 2026. The company will host a webcasted conference call at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss these resu", "url": "https://finance.yahoo.com/healthcare/articles/nautilus-biotechnology-announce-second-quarter-120000347.html", "source_name": "Market source", "published_at": "2026-07-09T06:11:14", "published_display": "09 Jul 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology to announce Q2 2026 results on July 28", "summary": "Nautilus Biotechnology, Inc. (NASDAQ: NAUT) will release its second-quarter 2026 financial results on July 28, 2026, before the market opens. Following the announcement, the company will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a busin", "url": "https://scanx.trade/stock-market-news/companies/nautilus-biotechnology-to-announce-q2-2026-results-on-july-28/45063864", "source_name": "scanx.trade", "published_at": "2026-07-08T15:39:57", "published_display": "08 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology sets July 28 call on Q2 results", "summary": "Nautilus Biotechnology (NASDAQ:NAUT) will release its second-quarter 2026 financial results before market open on Tuesday, July 28, 2026. Management will host a webcast conference call at 5:30 a.m. PT / 8:30 a.m. ET to discuss results, business developments, and outlook. Historic", "url": "https://www.stocktitan.net/news/NAUT/nautilus-biotechnology-to-announce-second-quarter-2026-financial-f06w9g3vl4nr.html", "source_name": "Stock Titan", "published_at": "2026-07-08T12:11:55", "published_display": "08 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Nautilus Biotechnology, Inc. \u2013 NASDAQ:NAUT", "summary": "This page displays the \"Price to sales forward\" metric for Nautilus Biotechnology, Inc. (NASDAQ: NAUT). It is a finance-related data point available on TradingView, specifically under the company's financial overview. The content provided appears to be a stub or a section of a la", "url": "https://www.tradingview.com/symbols/NASDAQ-NAUT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T06:39:57", "published_display": "08 Jul 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Nautilus Biotechnology, Inc. \u2013 NASDAQ:NAUT", "summary": "This article provides access to the \"Enterprise value to EBIT forward\" for Nautilus Biotechnology, Inc. (NASDAQ: NAUT) via the TradingView platform. It appears to be a financial data page rather than an analytical article, indicating where users can find this specific financial m", "url": "https://www.tradingview.com/symbols/NASDAQ-NAUT/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T06:10:12", "published_display": "08 Jul 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A Nautilus Biotechnology For: 30 June By Investing.com", "summary": "This article reports on a Form 13D/A filing for Nautilus Biotechnology concerning the period up to June 30th. It originates from Investing.com and was published on June 30, 2026, at 22:20. The filing likely pertains to significant ownership stakes and changes in beneficial owners", "url": "https://ng.investing.com/news/stock-market-news/form-13da-nautilus-biotechnology-for-30-june-93CH-2581117", "source_name": "Investing.com Nigeria", "published_at": "2026-07-01T04:39:22", "published_display": "01 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Andreessen Horowitz trims Nautilus (NAUT) stake in June 2026 block trade", "summary": "Andreessen Horowitz-affiliated funds have filed an amended Schedule 13D for Nautilus Biotechnology, Inc. (NAUT), disclosing a reduction in their stake following a block trade on June 26, 2026, at $2.00 per share. Despite the sale, AH Bio Fund II and Andreessen Horowitz LSV Fund I", "url": "https://www.stocktitan.net/sec-filings/NAUT/schedule-13d-a-nautilus-biotechnology-inc-amended-major-shareholder-r-d88621180b28.html", "source_name": "Stock Titan", "published_at": "2026-07-01T03:10:22", "published_display": "01 Jul 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology, Inc.(NasdaqCM: NAUT) added to Russell 2000 Growth Benchmark", "summary": "Nautilus Biotechnology, Inc. (NasdaqCM: NAUT) has been added to the Russell 2000 Growth Benchmark. This inclusion is part of several recent additions to various Russell indices, reflecting increased recognition and market exposure for the biotechnology company. Nautilus Biotechno", "url": "https://www.marketscreener.com/news/nautilus-biotechnology-inc-nasdaqcm-naut-added-to-russell-2000-growth-benchmark-ce7f5fded188f326", "source_name": "marketscreener.com", "published_at": "2026-06-30T04:39:22", "published_display": "30 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology, Inc.(NasdaqCM:NAUT) added to Russell Small Cap Comp Growth Benchmark", "summary": "Nautilus Biotechnology, Inc. (NasdaqCM: NAUT) has been added to the Russell Small Cap Comp Growth Benchmark. This inclusion is part of a series of additions to various Russell indices, including the Russell 2500 Growth, Russell 2000, and Russell Microcap indices. The company, foc", "url": "https://www.marketscreener.com/news/nautilus-biotechnology-inc-nasdaqcm-naut-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdc8bf020", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T21:40:35", "published_display": "29 Jun 2026 21:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology, Inc.(NasdaqCM:NAUT) added to Russell Small Cap Comp Value Benchmark", "summary": "Nautilus Biotechnology, Inc. (NAUT) has been added to the Russell Small Cap Comp Value Benchmark, as announced on June 28, 2026. This inclusion is part of a series of additions to various Russell indexes, including Growth, 2500, 2000, 3000E, and Microcap benchmarks, reflecting th", "url": "https://www.marketscreener.com/news/nautilus-biotechnology-inc-nasdaqcm-naut-added-to-russell-small-cap-comp-value-benchmark-ce7f5fdfd08ff52d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T16:40:11", "published_display": "29 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology, Inc.(NasdaqCM: NAUT) added to Russell 2000 Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNaHg1RmkwTDBUX1VoVmxlcEU3V3dSODA3eExRU09WQlZBal9Xb2M5N0lXbjRuVDlfNzlWZEtkbVNUM2VubmNmZmdReDFfblUtWGhvOG1xS2R5VXVQMmcyMm5WVS1PYWQzMTRrdFR3R19fRk5aWTdaWUFiMmxadDI5WUJRbE43NU1va3lrLVBCTERQQVozeVFzLUtEdEdUZXc2bi1JWElYajB1Zmgzcy00XzFoYm05X2FybUZ4amVR?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology, Inc.(NasdaqCM: NAUT) added to Russell Microcap Index", "summary": "Nautilus Biotechnology, Inc. (NasdaqCM: NAUT) has been added to the Russell Microcap Index, a significant development for the life sciences company. This inclusion follows its additions to the Russell Microcap Value, Microcap Growth, Russell 2000 Growth, and Russell 3000E Growth ", "url": "https://www.marketscreener.com/news/nautilus-biotechnology-inc-nasdaqcm-naut-added-to-russell-microcap-index-ce7f5fdedd89ff26", "source_name": "marketscreener.com", "published_at": "2026-06-29T05:40:43", "published_display": "29 Jun 2026 05:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology, Inc.(NasdaqCM: NAUT) added to Russell 2500 Value Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQTFYxVl9ZU1dpaVpfY1VERU9wQmM2WDhXVUpkT05FWlJFRExrRFVhUHg3aGNLZkd1QS04bmt0RHF0djlpUkdWT2pnQTNiS3RRX0p2QzI4MmpSdUtHNmJ4cElqb24wZVowWElkdEduY1ZUeWd4RFAwclV0dFY4Q1FnbzAyRDBVUDJFNDdmTVhjTTNzaVZkdjNxdnpfSGNUUUlvWE9KOGxLT2RjRThRTlFoUGVaa2o4cTFIWFhuZUwySDAtTENHaV9MMXlLbw?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T22:00:00+00:00", "published_display": "28 Jun 2026 22:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology, Inc.(NasdaqCM: NAUT) added to Russell 2500 Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNSjBJTTB0SWJfcDIwRkRZOWMzakhyeDhtUlZzY3RKcUp6N3NnaDVEM2l5Q0dmMHk4bDBEeDZnUllWaVRDa3diRV9iMXFHMU9hM3RNbTh2NWQ5TUU1QWVxTHh5UlRZUEhDS0dmV090cVlPeGpwYlFna2w2ZVBNdGdGTk1lV0FjbVRLUHBrWUhIcjB2dlVvRnhxSVVaYjI1emptSDdkVk5scTkwYUlOM01IM0ExZHp4OGRucDBibEpR?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T22:00:00+00:00", "published_display": "28 Jun 2026 22:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology, Inc.(NasdaqCM: NAUT) added to Russell 3000E Value Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxObjNQdVJ5bDRMbVo4Z2UyNWRSVlBOUG83T3RTTGRLR2V5a3dWcUNwLUN6Q1NjUFJXNG14bVFDaGFuX1NydnhKX3E4ZW5RdGF1LUhfVUp4V1JCWTJOTEs2dWlLcFVzR012ZWt1d0lSOHJMVTZoMDdrOWR1aTMzV2hYUlo5NTlLRkdYNzE3bVF6MHg2YWlrZkhYNHgzLUZIOWtiZzRxRTc5eC0zc080VUE2dF80dEpBckJKRUs2Q1AxQ1ZIdHRaNERNa0ZFal8?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology Inc (NAUT) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Nautilus Biotechnology Inc (NAUT), focusing on support, resistance, indicators, and moving averages. It highlights that the relevant support and resistance data have not been disclosed, and the technical indicators and moving averages", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-naut/technical", "source_name": "TradingKey", "published_at": "2026-06-27T02:38:55", "published_display": "27 Jun 2026 02:38", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnolgy, Inc. Actuals & Estimates (NASDAQ:NAUT)", "summary": "This article provides financial actuals and estimates for Nautilus Biotechnology, Inc. (NASDAQ:NAUT), detailing its stock performance, analyst forecasts, and historical price movements. It includes information on current stock price, market capitalization, earnings reports, and a", "url": "https://www.tradingview.com/symbols/NASDAQ-NAUT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T13:38:55", "published_display": "26 Jun 2026 13:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Nautilus Biotechnology Reports First Quarter 2026 Financial Results", "summary": "This press release details Nautilus Biotechnology's financial results for the first quarter of 2026. It will likely cover key financial metrics such as revenue, expenses, and net income for the period, along with any significant operational highlights or future outlook.", "url": "https://www.moomoo.com/news/post/69023619/press-release-nautilus-biotechnology-reports-first-quarter-2026-financial-results", "source_name": "Moomoo", "published_at": "2026-06-26T04:09:41", "published_display": "26 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NAUT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for Nautilus Biotechnology, Inc. (NAUT) stock, noting that one analyst currently offers a 1-year price target of $4.00. It also includes key financial data, stock performance metrics, and responses to frequently asked questions abo", "url": "https://www.tradingview.com/symbols/NASDAQ-NAUT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T01:10:03", "published_display": "26 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology (NAUT) grants 45,000 stock options to director", "summary": "Nautilus Biotechnology, Inc. (NAUT) granted 45,000 stock options to director Karen Akinsanya on June 18, 2026, as part of her compensation. The options have an exercise price of $2.28 per share and expire on June 18, 2036. They will vest in equal monthly installments over 12 mont", "url": "https://www.stocktitan.net/sec-filings/NAUT/form-4-nautilus-biotechnology-inc-insider-trading-activity-23d2e0a7f060.html", "source_name": "Stock Titan", "published_at": "2026-06-23T00:11:48", "published_display": "23 Jun 2026 00:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Nautilus Biotechnology, Inc. Insider Trading Activity", "summary": "Nautilus Biotechnology director Matthew S. McIlwain received a grant of 45,000 stock options, with an exercise price of $2.28 per share and an expiration date of June 18, 2036. These options will vest over time, with one-twelfth vesting monthly, conditional on his continued servi", "url": "https://www.stocktitan.net/sec-filings/NAUT/form-4-nautilus-biotechnology-inc-insider-trading-activity-4acae952c5d8.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:34", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Nautilus (NAUT) granted 45,000 stock options vesting monthly", "summary": "Nautilus Biotechnology director Melissa B. Epperly was granted 45,000 stock options with an exercise price of $2.28 per share, expiring on June 18, 2036. These options vest in equal monthly installments over 12 months, contingent on her continuous service as a \"Service Provider\" ", "url": "https://www.stocktitan.net/sec-filings/NAUT/form-4-nautilus-biotechnology-inc-insider-trading-activity-d0a346376b25.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:34", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology (NAUT) investors approve directors, auditor and annual Say on Pay", "summary": "Nautilus Biotechnology, Inc. (NAUT) held its 2026 annual meeting where shareholders approved the election of Class II directors Parag Mallick and Farzad Nazem, ratified PricewaterhouseCoopers LLP as the independent auditor for 2026, and gave advisory approval to the 2025 executiv", "url": "https://www.stocktitan.net/sec-filings/NAUT/8-k-nautilus-biotechnology-inc-reports-material-event-7cf711df1db9.html", "source_name": "Stock Titan", "published_at": "2026-06-18T19:40:34", "published_display": "18 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Inc (PBYI) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMib0FVX3lxTFBLTlZKRkozaEk4eERFcjZIb0ZibktCNnJNSkVzdmhCd0ZFRzROcll0TjJiTVBqeG5iWlhlSlFybFdsdkV4Qkw5RFB5Wmd5MDBkbFZ2Z1NZX1ZfV1pxcGNjZFk1dEZjR21FRWNUQ2RqOA?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T05:53:20+00:00", "published_display": "18 Jun 2026 05:53", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology Inc (NAUT) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Nautilus Biotechnology Inc (NAUT), noting that relevant data for key metrics like P/E, P/B, P/S, and P/CF ratios have not yet been disclosed by the company. It briefly shows the current stock price, market cap, and indicates that the", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-naut/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T20:40:00", "published_display": "17 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology Inc (NAUT) Institutional Confidence", "summary": "This article provides details on the institutional confidence in Nautilus Biotechnology Inc (NAUT), including its stock price, market cap, and a breakdown of its TradingKey Stock Score dimensions. It lists significant institutional shareholders and their shareholdings, offering i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-naut/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T17:39:44", "published_display": "17 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology Inc (NAUT) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Nautilus Biotechnology Inc (NAUT), including analyst ratings and target prices. Two analysts rate NAUT as a \"Strong Buy,\" with a target price of $2.50, representing an 84.33% upside. The company's recent EPS was -$0.11 against an exp", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-naut/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T16:39:44", "published_display": "17 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: PDS Biotechnology beats Q1 2026 EPS expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOUTY4SzBROHBQYlRIT2Y0U2NWN1NHN0hlSkJHNXZMamhvN1dpRWVpNlZKb3I4UDAtOVZRS2dqNzRiTWZISUtTdlZVbldnZ3pfV1N0VXh0NWV0ckpMcUZGRDdaZGlXSEFZWktvdHVreUladmplcUJXLUpMYUxpMVBIOEJWSlJodnJhZjBHMlN6dF8zVUlRWHlHblFQZ3dNa1FWUDJ4eVVNMWVZZ0dVaWtsZEhBcTB2bFNROXE3VXFYQ3NJWXIxYjRYZw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTXNUdVZadGlGUFRyY004aWwyQUQ1eUhVLVRxbUJtWTVrSndNdFV0S0xJYjdPTlhUVmNxVDl3Q2Y4VnE0d280bDh3QlFOOUNHS2JtRExnX0FfWHozeUNKVDhpRjJLbHZjdHdEQ0hldlRZbTFKdVNqWFEzRlFCbkNOclYweTJCcnNvXzFXWWVRWEhnSXVPbVJwSUJSbldKQlFXUF8zOTdKYlRxUQ?oc=5", "source_name": "TradingView", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology (NASDAQ:NAUT) Is In A Good Position To Deliver On Growth Plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQMmRMYjRMeGktTkxNcVREX2NoejM1UEQ1X1RaN2VubG5TQjhBay1feHJ2OG9NYzd3cG9wQkNTMmVoSDZzaFZ2cHhudnBEN0psRE41eV9taFM1Uks4cGF2eW1TcnA1MmRPYnV3Nm9nQVdaa3UwZ0h5dHYzWEZHV2lSdGh3eDRMQ0lvY19sUFBZNW03eEJXWl9xZXVNZ0pLaGpmNE5qYkRWWQ?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology Inc (NAUT) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/nautilus-biotechnology-inc-naut-q1-070513982.html", "source_name": "GuruFocus.com", "published_at": "2026-04-29T07:05:13+00:00", "published_display": "29 Apr 2026 07:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/e2e50c21-45bb-3616-8296-0ced8fb69ee7/nautilus-biotechnology-q1.html", "source_name": "MarketBeat", "published_at": "2026-04-28T15:29:04+00:00", "published_display": "28 Apr 2026 15:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQUTY3Q1hBZmZrNXh6OGNucnFIc0NOMWd4NWJ3V09IMklYZHA5SUd3YmhWSEowUVlhNVhreDR2ZUVLczdBSm5MVDVmbDhhU0VEZlhwSHdpT05nN2dONzZlR3hjeFhfMk5yQU5TSkZacEZnY0pobGU0eWNoeEVHNDJKOHZQM3ptTE5oUXRyeE1HV1dmdzUxLW9GaElR?oc=5", "source_name": "Investing News Network", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is Why Nautilus Biotechnology (NAUT) is One of the Best Life Sciences Penny Stocks to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNOGlKa3VLUTFtQVNPVjRmeFlZZjdJUURSa1IxT0RnMlBYUUhFeklMNnI5TkpvYzZiVHp6bUJ6YUN5WXJHZk9QTjBpRm53bG5YLXh0MjlfcFYtQUpTQWMxRmVxT3o1UnNUbjBEUXBydjBteUdwWG1jd2g2UHpQa1lvM2F4VWphQ1BKakV1bUM0OFBXWk5Oa3E5aGdQNVpiUEhDYkZjUTg5WQ?oc=5", "source_name": "Market source", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology And 2 Other Compelling Penny Stocks For Your Watchlist", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQMlozM2lReGNNRlVEX2s0T3hfRTcwVEx4Ulo4TnVRZEpieWI4M1R0LUp6MjhlTkJpT3ctYTM4aW1TeklmM2tPZTRpdUx6NUNSVGFyYWNPZW1jWlNWMUNHZkpPR0JORThLREUwTFg1dmJyUmNNTTFRVmg4eHBnWm9sNzdtYWFSRmNpbnBJc25PakRiVDd2cm94eXNZYU9MRTdpSjVkZ3FtVlhiUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOTlBxUW9QV2o3YTF4RVdzWWlWUWZfU2V6Y25mcHBxM2RQTkpES0FqY0xsRDdtc0NqZE1KY2RFSWFfMGVCSVR2RXpndERPOFF6al9HQndCU2p0SkpPQ3dsc19BaVVvSzFxQ2FwcGEwVFlxNUFmZUUtdHpvVmpfQkFDX2FVLXprUQ?oc=5", "source_name": "Market source", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology Insiders May Regret Not Buying More, Market Cap Hits US$236m", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NAUT Stock Price and Chart \u2014 NASDAQ:NAUT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE4yTFRZV25WbVN4Mk1xQ2ZBQUZRNWozUTM2NUVhQXprREZDcjBfXzZYeW1TTjZ0cHBQdjgwVXZ6MTh6MUpMZWZzSXpQcDhwU256UDZOOENkZHJmMmRh?oc=5", "source_name": "TradingView", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top Nautilus Biotechnology (NAUT) Competitors 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVNKY3laekE3VnVNaGdPS05PUzV0MkxNb1dXNFRlNmhHWnpVcnlhZnlkUWZoV05DaEhvVE9yU2djeV9tR1I2NU5yNHlVTnFQWGNuWGhFcEpNcklyTkNHWGs1LTNTYjRfemhTSHhlQnkzVWVIR0o3WTYtMTJTOXR3VQ?oc=5", "source_name": "MarketBeat", "published_at": "2021-06-13T14:46:49+00:00", "published_display": "13 Jun 2021 14:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nautilus Biotechnology (NAUT) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9nSlZVc2pVUjFHaVZRb3ZMNTg4N09INjF1R251OVN1Y1EwVHFuWWJmQzFTOFMwN2pBMXViQjBwMXI0akhtdHU0ODhWU0ZsVWNlSzN1NFNHT3pUUQ?oc=5", "source_name": "MarketBeat", "published_at": "2021-06-13T14:24:51+00:00", "published_display": "13 Jun 2021 14:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 83, "total_relevant": 55, "sentiment_summary": {"positive": 11, "negative": 4, "neutral": 40, "score": 52, "total": 55, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 15.4, "count": 28}, {"event": "earnings", "label": "Earnings", "weight": 12.65, "count": 23}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 11, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 1.89, "latest_week": "2026-07-10", "one_week_move": 9.2, "four_week_move": -15.6, "twelve_week_move": -37.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.947234, "market_dynamics_buy_signal": false, "relative_strength": -12.208053, "fair_value_gap": -12.4, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 41.3123, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+9.2% over one week, -15.6% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 60, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "TradingView", "count": 8}, {"label": "Stock Titan", "count": 6}, {"label": "marketscreener.com", "count": 6}, {"label": "TradingKey", "count": 5}, {"label": "simplywall.st", "count": 4}, {"label": "MarketBeat", "count": 3}, {"label": "www.marketscreener.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 55}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 28}, {"label": "Earnings", "count": 23}, {"label": "Balance sheet", "count": 1}, {"label": "Deals and strategy", "count": 1}, {"label": "Analyst action", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "55", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+9.2% over one week, -15.6% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks"}], "updated_at": "2026-07-15T23:34:00.171397+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}